N/A
Manufactured by Chain Drug Marketing Assoc., Inc.
76 FDA adverse event reports analyzed
Last updated: 2026-04-15
TETRAHYDROZOLINE HCL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Chain Drug Marketing Assoc., Inc.. The most commonly reported adverse reactions for TETRAHYDROZOLINE HCL include FATIGUE, ALANINE AMINOTRANSFERASE INCREASED, ASPARTATE AMINOTRANSFERASE INCREASED, ASTHENIA, BLOOD ALKALINE PHOSPHATASE INCREASED. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for TETRAHYDROZOLINE HCL.
Out of 13 classified reports for TETRAHYDROZOLINE HCL:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 76 FDA FAERS reports that mention TETRAHYDROZOLINE HCL. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include FATIGUE, ALANINE AMINOTRANSFERASE INCREASED, ASPARTATE AMINOTRANSFERASE INCREASED, ASTHENIA, BLOOD ALKALINE PHOSPHATASE INCREASED, DYSGEUSIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Chain Drug Marketing Assoc., Inc. in connection with TETRAHYDROZOLINE HCL. Always verify the specific product and NDC with your pharmacist.